Harmine inhibits tumour specific neo-vessel formation by regulating VEGF, MMP, TIMP and pro-inflammatory mediators both in vivo and in vitro

European Journal of Pharmacology

Volumn 649, Issue 1-3, 2010, Pages 64-73

  Hamsa, T P ^a   Kuttan, Girija ^a  

^a AMALA CANCER RESEARCH CENTRE   (India)

Author keywords

Anti angiogenesis; B16F 10 melanoma; Harmine; Pro inflammatory cytokine; Transcription factor; VEGF

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOOXYGENASE 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HARMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; C57BL 6 MOUSE; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA; MELANOMA CELL; MIGRATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; HARMINE; HUMANS; INFLAMMATION MEDIATORS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICROVESSELS; NEOVASCULARIZATION, PATHOLOGIC; RATS; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 78049243460     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.09.010     Document Type: Article

References (58)

1. Abe A., Yamada H. Harmol induces apoptosis by caspase-8 activation independently of Fas/Fas ligand interaction in human lung carcinoma H596 cells. Anticancer Drugs 2009, 20:373-381.
2. Adams R.H., Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat. Rev. Mol. Cell Biol. 2007, 8:464-478.
3. Albini A., Iwamoto Y., Kleinman H.K., Martin G.R., Aaronson S.A., Kozlowski J.M., McEwan R.N. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 1987, 47:3239-3245.
4. Apte R.N., Voronov E. Interleukin-1 - a major pleiotropic cytokine in tumor-host interactions. Semin. Cancer Biol. 2002, 12:277-290.
5. Arshad N., Zitterl-Eglseer K., Hasnain S., Hess M. Effect of Peganum harmala or its beta-carboline alkaloids on certain antibiotic resistant strains of bacteria and protozoa from poultry. Phytother. Res. 2008, 22:1533-1538.
6. Berrougui H., Martin-Cordero C., Khalil A., Hmamouchi M., Ettaib A., Marhuenda E., Herrera M.D. Vasorelaxant effects of harmine and harmaline extracted from Peganum harmala L. seeds in isolated rat aorta. Pharmacol. Res. 2006, 54:150-157.
7. Bhat T.A., Singh R.P. Tumor angiogenesis - a potential target in cancer chemoprevention. Food Chem. Toxicol. 2008, 46:1334-1345.
8. Billings P.C., Habres J.M., Liao D.C., Tuttle S.W. Human fibroblasts contain a proteolytic activity which is inhibited by the Bowman-Birk protease inhibitor. Cancer Res. 1991, 51:5539-5543.
9. Boosani C.S., Mannam A.P., Cosgrove D., Silva R., Hodivala-Dilke K.M., Keshamouni V.G., Sudhakar A. Regulation of COX-2 mediated signaling by alpha3 type IV noncollagenous domain in tumor angiogenesis. Blood 2007, 110:1168-1177.
10. Brakenhielm E., Cao R., Cao Y. Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J. 2001, 15:1798-1800.
11. Brivio F., Lissoni P., Rovelli F., Nespoli A., Uggeri F., Fumagalli L., Gardani G. Effects of IL-2 preoperative immunotherapy on surgery-induced changes in angiogenic regulation and its prevention of VEGF increase and IL-12 decline. Hepatogastroenterology 2002, 49:385-387.
12. Bussolino F., Ziche M., Wang J.M., Alessi D., Morbidelli L., Cremona O., Bosia A., Marchisio P.C., Mantovani A. in vitro and in vivo activation of endothelial cells by colony-stimulating factors. J. Clin. Invest. 1991, 87:986-995.
13. Campling B.G., Pym J., Baker H.M., Cole S.P., Lam Y.M. Chemosensitivity testing of small cell lung cancer using the MTT assay. Br. J. Cancer 1991, 63:75-83.
14. Chen Q., Chao R., Chen H., Hou X., Yan H., Zhou S., Peng W., Xu A. Antitumor and neurotoxic effects of novel harmine derivatives and structure-activity relationship analysis. Int. J. Cancer 2005, 114:675-682.
15. Cole S.P. Rapid chemosensitivity testing of human lung tumor cells using the MTT assay. Cancer Chemother. Pharmacol. 1986, 17:259-263.
16. Cuezva J.M., Krajewska M., de Heredia M.L., Krajewski S., Santamaria G., Kim H., Zapata J.M., Marusawa H., Chamorro M., Reed J.C. The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res. 2002, 62:6674-6681.
17. D'Amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci. USA 1994, 91:4082-4085.
18. Dignam J.D., Lebovitz R.M., Roeder R.G. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 1983, 11:1475-1489.
19. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood 1996, 87:2095-2147.
20. Dormond O., Bezzi M., Mariotti A., Ruegg C. Prostaglandin E2 promotes integrin alpha Vbeta 3-dependent endothelial cell adhesion, rac-activation, and spreading through cAMP/PKA-dependent signaling. J. Biol. Chem. 2002, 277:45838-45846.
21. Dvorak H.F. Angiogenesis: update 2005. J. Thromb. Haemost. 2005, 3:1835-1842.
22. Feldman A.L., Libutti S.K. Progress in antiangiogenic gene therapy of cancer. Cancer 2000, 89:1181-1194.
23. Ferrara N. VEGF: an update on biological and therapeutic aspects. Curr. Opin. Biotechnol. 2000, 11:617-624.
24. Fotsis T., Pepper M.S., Aktas E., Breit S., Rasku S., Adlercreutz H., Wahala K., Montesano R., Schweigerer L. Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res. 1997, 57:2916-2921.
25. Gasparini G., Longo R., Sarmiento R., Morabito A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?. Lancet Oncol. 2003, 4:605-615.
26. Gomez D.E., Alonso D.F., Yoshiji H., Thorgeirsson U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell Biol. 1997, 74:111-122.
27. Gomez M., Luque A., del Pozo M.A., Hogg N., Sanchez-Madrid F., Cabanas C. Functional relevance during lymphocyte migration and cellular localization of activated beta1 integrins. Eur. J. Immunol. 1997, 27:8-16.
28. Goodwin A.M. in vitro assays of angiogenesis for assessment of angiogenic and anti-angiogenic agents. Microvasc. Res. 2007, 74:172-183.
29. Green L.C., Wagner D.A., Glogowski J., Skipper P.L., Wishnok J.S., Tannenbaum S.R. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal. Biochem. 1982, 126:131-138.
30. Griffioen A.W., Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev. 2000, 52:237-268.
31. Guo H.B., Lee I., Kamar M., Akiyama S.K., Pierce M. Aberrant N-glycosylation of beta1 integrin causes reduced alpha5beta1 integrin clustering and stimulates cell migration. Cancer Res. 2002, 62:6837-6845.
32. Gupta K., Kshirsagar S., Chang L., Schwartz R., Law P.Y., Yee D., Hebbel R.P. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res. 2002, 62:4491-4498.
33. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997, 277:48-50.
34. Huang Y.T., Hwang J.J., Lee P.P., Ke F.C., Huang J.H., Huang C.J., Kandaswami C., Middleton E., Lee M.T. Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor. Br. J. Pharmacol. 1999, 128:999-1010.
35. Ishida J., Wang H.K., Bastow K.F., Hu C.Q., Lee K.H. Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs. Bioorg. Med. Chem. Lett. 1999, 9:3319-3324.
36. Jaffe E.A., Nachman R.L., Becker C.G., Minick C.R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Invest. 1973, 52:2745-2756.
37. Kang S., Kim Y.B., Kim M.H., Yoon K.S., Kim J.W., Park N.H., Song Y.S., Kang D., Yoo K.Y., Kang S.B., Lee H.P. Polymorphism in the nuclear factor kappa-B binding promoter region of cyclooxygenase-2 is associated with an increased risk of bladder cancer. Cancer Lett. 2005, 217:11-16.
38. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
39. Kofler S., Nickel T., Weis M. Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation. Clin. Sci. (Lond) 2005, 108:205-213.
40. Kubota Y., Kleinman H.K., Martin G.R., Lawley T.J. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J. Cell Biol. 1988, 107:1589-1598.
41. Lal B.K., Varma S., Pappas P.J., Hobson R.W., Duran W.N. VEGF increases permeability of the endothelial cell monolayer by activation of PKB/akt, endothelial nitric-oxide synthase, and MAP kinase pathways. Microvasc. Res. 2001, 62:252-262.
42. Lampugnani M.G. Cell migration into a wounded area in vitro. Methods Mol. Biol. 1999, 96:177-182.
43. Leyon P.V., Kuttan G. Effect of Tinospora cordifolia on the cytokine profile of angiogenesis-induced animals. Int. Immunopharmacol. 2004, 4:1569-1575.
44. Maruno M., Kovach J.S., Kelly P.J., Yanagihara T. Distribution of endogenous tumour necrosis factor alpha in gliomas. J. Clin. Pathol. 1997, 50:559-562.
45. Masson V.V., Devy L., Grignet-Debrus C., Bernt S., Bajou K., Blacher S., Roland G., Chang Y., Fong T., Carmeliet P., Foidart J.M., Noel A. Mouse aortic ring assay: a new approach of the molecular genetics of angiogenesis. Biol. Proced. Online 2002, 4:24-31.
46. Moura D.J., Richter M.F., Boeira J.M., Pegas Henriques J.A., Saffi J. Antioxidant properties of beta-carboline alkaloids are related to their antimutagenic and antigenotoxic activities. Mutagenesis 2007, 22:293-302.
47. Neville M.E., Robb R.J., Popescu M.C. In situ vaccination against a non-immunogenic tumour using intratumoural injections of liposomal interleukin-2. Cytokine 2001, 16:239-250.
48. Ono M., Torisu H., Fukushi J., Nishie A., Kuwano M. Biological implications of macrophage infiltration in human tumor angiogenesis. Cancer Chemother. Pharmacol. 1999, 43(Suppl):S69-S71.
49. Reinders M.E., Sho M., Izawa A., Wang P., Mukhopadhyay D., Koss K.E., Geehan C.S., Luster A.D., Sayegh M.H., Briscoe D.M. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J. Clin. Invest. 2003, 112:1655-1665.
50. Roberts W.G., Palade G.E. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res. 1997, 57:765-772.
51. Sethi G., Sung B., Aggarwal B.B. TNF: a master switch for inflammation to cancer. Front. Biosci. 2008, 13:5094-5107.
52. Sheeja K., Guruvayoorappan C., Kuttan G. Antiangiogenic activity of Andrographis paniculata extract and andrographolide. Int. Immunopharmacol. 2007, 7:211-221.
53. Shen Z., Peedikayil J., Olson G.K., Siebert P.D., Fang Y. Multiple transcription factor profiling by enzyme-linked immunoassay. Biotechniques 2002, 32(5):1168, 1170-2, 1174 passim.
54. Weidner N., Semple J.P., Welch W.R., Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J. Med. 1991, 324:1-8.
55. Zaric J., Ruegg C. Integrin-mediated adhesion and soluble ligand binding stabilize COX-2 protein levels in endothelial cells by inducing expression and preventing degradation. J. Biol. Chem. 2005, 280:1077-1085.
56. Zhou J.R., Gugger E.T., Tanaka T., Guo Y., Blackburn G.L., Clinton S.K. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J. Nutr. 1999, 129:1628-1635.
57. Zhu W.H., Nicosia R.F. The thin prep rat aortic ring assay: a modified method for the characterization of angiogenesis in whole mounts. Angiogenesis 2002, 5:81-86.
58. Zhu W.H., Guo X., Villaschi S., Francesco Nicosia R. Regulation of vascular growth and regression by matrix metalloproteinases in the rat aorta model of angiogenesis. Lab. Investig. 2000, 80:545-555.